Clinical Features and Treatment Outcomes of HIV-Associated Cryptococcal Meningitis

0
0
0

Clinical Features and Treatment Outcomes of Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: A 2-Year Retrospective Analysis

Cryptococcal meningitis (CM), caused by Cryptococcus neoformans, remains a significant opportunistic infection among individuals with advanced human immunodeficiency virus (HIV) infection. This retrospective study analyzed 101 patients with first-diagnosed HIV-associated CM admitted to the Shanghai Public Health Clinical Center from September 2013 to December 2016. The investigation aimed to characterize clinical presentations, treatment responses, and prognostic factors over a 2-year follow-up period, providing insights into the management of this life-threatening condition.

Study Design and Patient Characteristics

The study included 101 patients with confirmed HIV-associated CM, diagnosed through cerebrospinal fluid (CSF) positivity for Indian ink staining or fungal culture. Baseline demographics revealed a median age of 35 years (interquartile range [IQR]: 29.5–43.0), with 87.1% (88/101) being male. A majority (85.1%, 86/101) were antiretroviral therapy (ART)-naïve at admission, underscoring late HIV diagnosis or poor adherence to treatment. Immunologically, 86.9% (86/99) had CD4+ T-cell counts 1,000 copies/mL) were observed in 95.5% (64/67) of patients, highlighting profound immunosuppression.

Diagnostic delays were common: 56.4% (57/101) experienced ≥14 days between symptom onset and CM diagnosis. Clinical features included headache (93.1%, 94/101), fever (81.2%, 82/101), and vomiting (34.7%, 35/101). Altered mental status (Glasgow Coma Scale <15) was present in 16.8% (17/101), a critical marker of disease severity.

Laboratory and Radiological Findings

CSF analysis demonstrated high diagnostic sensitivity for cryptococcal antigen (100%, 96/96), fungal culture (99%, 98/99), and Indian ink staining (98%, 98/101). Strikingly, 42.4% (42/99) exhibited normal CSF cell counts and biochemical parameters (cell count <20 cells/mL, protein <500 mg/L, glucose ≥2.0 mmol/L), emphasizing the limitations of routine CSF tests in immunocompromised hosts. Blood cultures were positive for C. neoformans in 73.2% (60/82), indicating disseminated infection.

Intracranial imaging abnormalities were detected in 67.6% (50/74) of patients. Lesions were predominantly located around the ventricles (40%), basal ganglia (38%), and frontal lobes (38%). Multiple lesions (>1) occurred in 48% (24/50), reflecting aggressive disease progression.

Comorbidities and Coinfections

Concurrent infections complicated management: 29.7% (30/101) had Pneumocystis jirovecii pneumonia (PCP) at admission, while 40.2% (37/92) presented with cryptococcal pneumonia. During follow-up, 30.7% (27/88) developed mycobacterial infections, further straining immune recovery.

Treatment Regimens and Outcomes

Antifungal Therapy

All patients received induction therapy with conventional amphotericin B (AMB; 0.5 mg/kg/day) plus flucytosine (5-FC; 100 mg/kg/day) for ≥4 weeks, followed by consolidation with fluconazole (400 mg/day) until CSF Indian ink negativity. Maintenance therapy with fluconazole (200 mg/day) continued until CD4+ counts exceeded 100 cells/mm³. The median duration of AMB and 5-FC use was 43 days (IQR: 31.5–68.5) and 70 days (IQR: 36.5–116.5), respectively.

Voriconazole (VOR) was added during the first two weeks in 55.4% (56/101) of cases, primarily based on physician discretion and patient affordability. Ventriculoperitoneal shunts were required in 10.9% (11/101) to manage intracranial hypertension.

Microbiological and Clinical Responses

CSF cultures turned negative at a median of 20 days (IQR: 15–30), while CSF Indian ink negativity occurred at 8.5 months (IQR: 3.25–12.0). By the end of the study, only 43.6% (44/101) achieved CSF Indian ink clearance. ART initiation before CM diagnosis significantly accelerated fungal clearance: ART-treated patients achieved negativity at 7 months versus 12 months in ART-naïve individuals (P < 0.001).

Mortality and Prognostic Factors

All-cause mortality rates were 10.1% (10/99) at 2 weeks, 18.9% (18/95) at 8 weeks, and 20.7% (19/92) at 2 years. Multivariate analysis identified two independent predictors of 8-week mortality:

  1. PCP coinfection (adjusted odds ratio [AOR]: 3.933; 95% CI: 1.166–13.269; P = 0.027).
  2. Altered mental status (AOR: 9.574; 95% CI: 2.548–35.974; P = 0.001).

Patients with PCP had a 35.5% mortality rate versus 11.9% in non-coinfected counterparts. Similarly, altered mentation correlated with a 52.9% mortality rate compared to 11.5% in those with normal mental status.

Adverse Events and Safety

Adverse events were common but manageable. Hypokalemia (61.8%, 58/94), anemia (72.3%, 68/94), and elevated alanine aminotransferase (ALT; 65.9%, 62/94) predominated. VOR use increased ALT elevation (90.4% vs. 34.8% in the 2-drug group; P < 0.001) but did not exacerbate severe (Grade 3/4) events. No differences in nephrotoxicity, neutropenia, or thrombocytopenia were observed between treatment groups.

Disease Complications and Immune Reconstitution

New or progressive intracranial lesions occurred in 29.4% (15/51) during treatment, likely reflecting immune reconstitution inflammatory syndrome (IRIS) post-ART initiation. Mycobacterial infections emerged in 30.7% (27/88), underscoring the complexity of managing advanced HIV with overlapping opportunistic infections.

Discussion and Clinical Implications

This study highlights the challenges of HIV-associated CM in a resource-constrained setting. Key findings include:

  1. Diagnostic Delays: Over half of patients experienced ≥14-day delays in diagnosis, contributing to advanced disease. Reliance on specialized tests (e.g., cryptococcal antigen) is critical, as routine CSF parameters often remain normal.
  2. Immune Suppression: Median CD4+ counts of 20 cells/mm³ and high ART-naïve rates (85.1%) reflect late HIV presentation. Earlier ART initiation and routine cryptococcal antigen screening in high-risk populations could mitigate mortality.
  3. Treatment Response: Prolonged fungal clearance (median 8.5 months) and high mortality (20.7% at 2 years) emphasize the need for optimized induction regimens. While adjunctive VOR did not reduce mortality, its role in refractory cases warrants further study.
  4. Prognostic Markers: Altered mental status and PCP coinfection emerged as critical mortality predictors, guiding risk stratification and intensive care prioritization.

Limitations include the retrospective design, potential selection bias in VOR use, and incomplete CSF follow-up data. Prospective studies are needed to validate these findings and explore novel therapies.

Conclusion

HIV-associated CM remains a lethal complication of advanced immunosuppression, characterized by delayed diagnosis, high fungal burden, and significant mortality. Early ART, aggressive antifungal therapy, and vigilant monitoring for PCP coinfection and neurological deterioration are essential to improving outcomes. The study underscores the importance of integrating cryptococcal antigen screening into HIV care protocols and optimizing access to rapid diagnostics in resource-limited settings.

doi.org/10.1097/CM9.0000000000001191

Was this helpful?

0 / 0